Payment overview · 2025
General Payments
$193.71
8 reported records · 3 companies
Healthcare provider profile · identity verified
Vincent Wu
Allopathic & Osteopathic Physicians|Family Medicine · SPRING HILL, FL · NPI 1962999490
Verified facts
What the public records show
CMS Open Payments records show Vincent Wu received $193.71 in general payments during 2025 across 8 reported records.
GlaxoSmithKline, LLC. accounted for 45.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.05 | 45.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.90 | 39.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.76 | 14.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $193.71 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $88.05 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.90 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 562 | 178 |
| Lisinopril | Lisinopril | 428 | 140 |
| Losartan Potassium | Losartan Potassium | 376 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 301 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 296 | 93 |
| Omeprazole | Omeprazole | 294 | 91 |
| Gabapentin | Gabapentin | 213 | 72 |
| Metformin Hcl | Metformin Hcl | 184 | 64 |
| Simvastatin | Simvastatin | 184 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 52 |
| Furosemide | Furosemide | 166 | 62 |
| Trazodone Hcl | Trazodone Hcl | 153 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 60 |
| Glipizide Er | Glipizide | 143 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 38 |
| Alprazolam | Alprazolam | 131 | 30 |
| Methylprednisolone | Methylprednisolone | 124 | 102 |
| Tramadol Hcl | Tramadol Hcl | 124 | 35 |
| Meloxicam | Meloxicam | 115 | 51 |
| Metformin Hcl Er | Metformin Hcl | 109 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 107 | 49 |
| Ezetimibe | Ezetimibe | 102 | 39 |
| Alendronate Sodium | Alendronate Sodium | 95 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 92 | 15 |
| Clonidine Hcl | Clonidine Hcl | 90 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 36 |
| Allopurinol | Allopurinol | 82 | 25 |
| Atenolol | Atenolol | 79 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 77 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 22 |
| Meclizine Hcl | Meclizine Hcl | 76 | 38 |
| Carvedilol | Carvedilol | 75 | 24 |
| Azithromycin | Azithromycin | 74 | 67 |
| Sertraline Hcl | Sertraline Hcl | 74 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 22 |
| Famotidine | Famotidine | 69 | 30 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 68 | 22 |
| Warfarin Sodium | Warfarin Sodium | 68 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 13 |
| Potassium Chloride | Potassium Chloride | 66 | 26 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Lovastatin | Lovastatin | 59 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 59 | 18 |
| Finasteride | Finasteride | 58 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 12 |
| Temazepam | Temazepam | 50 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 13 |
| Fenofibrate | Fenofibrate,micronized | 47 | 15 |
| Ozempic | Semaglutide | 47 | 14 |
| Buspirone Hcl | Buspirone Hcl | 46 | 21 |
| Montelukast Sodium | Montelukast Sodium | 45 | 18 |
| Ondansetron Odt | Ondansetron | 44 | 24 |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 42 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 13 |
| Donepezil Hcl | Donepezil Hcl | 39 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 13 |
| Eliquis | Apixaban | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 12 |
| Prednisone | Prednisone | 34 | 21 |
| Glipizide | Glipizide | 33 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 22 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Tadalafil | Tadalafil | 30 | 16 |
| Ibuprofen | Ibuprofen | 29 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Baclofen | Baclofen | 18 | suppressed |
| Benzonatate | Benzonatate | 18 | 16 |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $193.71 · 8 records | GlaxoSmithKline, LLC. | AREXVY, BREZTRI, ELIQUIS, NURTEC ODT, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error